PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-20.40%
Negative net income growth while AVXL stands at 51.67%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
5.37%
Some D&A expansion while AVXL is negative at -100.00%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
42.67%
Lower deferred tax growth vs. AVXL's 100.00%, implying fewer future tax liabilities. David Dodd would confirm there’s no short-term tax shock instead.
-15.52%
Both cut yoy SBC, with AVXL at -76.51%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
2.45%
Slight usage while AVXL is negative at -197.62%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-64.66%
Negative yoy AP while AVXL is 100.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
389.89%
Some yoy usage while AVXL is negative at -100.59%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-15.52%
Both negative yoy, with AVXL at -21487.30%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-26.74%
Both yoy CFO lines are negative, with AVXL at -69.25%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
51.76%
CapEx growth of 51.76% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative yoy purchasing while AVXL stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
No Data
No Data available this quarter, please select a different quarter.
169.66%
Growth of 169.66% while AVXL is zero at 0.00%. Bruce Berkowitz sees a moderate difference requiring justification by ROI in these smaller invests.
253.33%
We expand invests by 253.33% while AVXL is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
100.00%
Debt repayment similar to AVXL's 100.00%. Walter Schloss sees parallel liability management or similar free cash flow availability.
-79.28%
Negative yoy issuance while AVXL is 1014.18%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.